Founders & management

Founded in 2005, by Alexandre TOKAY, CEO, and Dr. Michel KHRESTCHATISKY, Scientific Advisor, VECT-HORUS is a spin-off of the NICN UMR7259 (CNRS and Aix-Marseille University) now Institute for NeuroPhysiopathology (INP) directed by Dr. Michel KHRESTCHATISKY (UMR7051, CNRS AMU). Based in Marseille, France, the company has 30 employees, mostly in R&D, under the responsibility of Dr. Jamal TEMSAMANI, Head of Drug Development.

Alexandre TOKAY 
Alexandre TOKAY
CEO and cofounder
Michel KHRESTCHATISKY 
Michel KHRESTCHATISKY
Co-founder and scientific counsel
Jamal TEMSAMANI 
Jamal TEMSAMANI
Drug Development and Corporate

Scientific advisory board

Five renowned scientists and experts in neuropharmacology, oncology and molecular engineering bring their expertise to VECT-HORUS.

Pr. Jean-Michel SCHERRMANN 
Pr. Jean-Michel SCHERRMANN
PharmD, PhD
Dr. Vincent DIVE 
Dr. Vincent DIVE
PhD
Dr. Mikhail KALINICHEV 
Dr. Mikhail KALINICHEV
PhD
Pr. Pascal HAMMEL 
Pr. Pascal HAMMEL
MD
Pr. Frédéric COURBON 
Pr. Frédéric COURBON
PhD

Partners

Financial partners

VECT-HORUS continues its funding strategy with historic shareholders and also new entrants to grant the Company significant financial resources to carry out its research and development programs and leverage with public research grants.

Banque Populaire bpifrance Crédit Agricole
Protisvalor Financière tuileries co-invest

Academic partners

Close collaborations with top academic research centres: CNRS, AMU, CEA, INSERM

CNRS Aix-Marseille université CEA INSERM

Member of health sector clusters: DHUNE, Eurobiomed